If two forthcoming US approval decisions go Regeneron Pharmaceuticals Inc.'s way – for the rheumatoid arthritis therapy sarilumab in October and the atopic dermatitis treatment dupilumab in the first half of 2017 – those products could offset a slowdown in Eylea's sales growth. The company doesn't expect a near-term or immediate decline, but executives noted that it was important to discuss challenges in the marketplace for vascular endothelial growth factor (VEGF) inhibitors that treat wet age-related macular degeneration (AMD) and other eye diseases.
Eylea "is one of our most important approved products and continues to grow well globally. Eylea is now at an...








